Dr Lal PathLabs on Thursday reported a 53% year-on-year (YoY) rise in consolidated net profit at ₹81 crore in the third quarter ended December 31, 2023, compared to ₹52.8 crore in the corresponding quarter of last year.
The healthcare company's revenue jumped 10% to ₹5,389 crore in Q3FY24, compared to ₹4,894 crore in Q3FY23.
Earnings before interest, tax, depreciation, ammortisation (EBITDA) rose 24.5% YoY to ₹140.6 crore. The EBITDA margins improved to 26.1%.
The company will also pay ₹12 per equity share as the second interim dividend for financial year 2023-24. The record date for the purpose of payment of the second interim dividend will be February 13, 2024.
Shares of Dr Lal PathLabs Ltd were trading 0.25% lower at ₹2,511 apiece on the NSE. The stock has risen over 20% in the last one year.
First Published: Feb 1, 2024 2:25 PM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Lok Sabha Election 2024 — how regional parties are challenging national giants in Phase-4
May 15, 2024 6:17 AM
Supreme Court refuses plea seeking 6-year poll ban on PM
May 14, 2024 7:14 PM
Punjab Lok Sabha elections 2024: A look at BJP candidates
May 14, 2024 7:06 PM
Lok Sabha polls: EC disposes of 90% complaints related to MCC violations
May 14, 2024 4:45 PM